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1. Introduction  
IgA nephropathy (IgAN), also known as Berger’s disease, is the most common primary 
glomerular disease world wide and a significant cause of end-stage renal disease (ESRD) in 
many parts of the world (Floege & Feehally, 2000; Geddes et al., 2003; Julian et al., 1988). It 
was first described in 1968 in Paris, France (Berger & Hingalis, 1968), but now the disease is 
known to have a cosmopolitan distribution (Ballardie et al., 1987; Chandrika, 2009; D’Amico, 
1985; Koyama et al., 1997; Lai et al., 1999; Mubarak, 2009; Power et al., 185; Rivera et al., 
2004; Schena, 1997; Seedat et al., 1988; Sinniah, 1980; Strata P, et al., 1995; Yahya et al., 1997). 
Significant advancements have been made during last four decades in understanding the 
etiology, pathogenesis, classification, and treatment of this enigmatic disease. In this 
chapter, we discuss briefly about the historical background, epidemiology, etiology, 
pathogenesis, pathology, treatment, and recent developments in the diagnosis and 
prognosis of IgAN with particular emphasis on a recent clinicopathological classification 
developed through international collaboration by the members of International IgAN 
network in conjunction with renal pathology society (RPS). This classification is simple, easy 
to apply, fairly reproducible, and clinically pre-validated, and provides a role model for 
classifying other renal diseases in similar manner.   
2. Historical background 
IgAN was first described by Berger and Hingalis in France in 1968 as a renal glomerular 
disease characterized by the predominant or co-dominant IgA containing immune complex 
deposits in the mesangium of the glomeruli (Berger & Hingalis, 1968). Thus, its diagnosis 
required, and still so, the histopathologic and immunoflourescence (IF) evaluation of the 
invasive procedure of renal biopsy. No blood or urinary test has been developed yet to 
replace the renal biopsy for its accurate diagnosis. Traditionally, the disease was considered 
to be a benign disease, due mainly to its very slow rate of progression, as is apparent from 
its earlier synonym of “benign familial hematuria” and to be confined to France. However, 
soon it was realized, as evidence accumulated from subsequent long term follow-up studies 
from different parts of the world, that both the above assumptions about IgAN were wrong, 
as will be discussed below in the epidemiology and the prognosis of the disease.  
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3. Epidemiology and magnitude of the problem 
The epidemiology of IgAN is both interesting and intriguing in that, although 
cosmopolitan in distribution, there is a significant variability in the reported incidence 
and prevalence of the disease in different countries. Very few population based incidence 
studies on IgAN have been reported in the literature. The reported incidence in different 
parts of Western Europe has varied from 15 to 40 new cases per million population per 
year (Rivera et al., 2004; Schena, 1997; Strata P, et al., 1995).  Majority of the studies have 
calculated the frequency of IgAN as a percent of all native renal biopsies performed for a 
variety of clinical indications. The highest prevalence (upto 60%) has been reported in 
native renal biopsy series from Japan, Korea, China, Singapore, Western Europe, and 
Australia (Ballardie et al., 1987; D’Amico, 1985; Kazi et al., 2009; Koyama et al., 1997; Lai et 
al., 1999; Power et al., 185; Rivera et al., 2004; Schena, 1997; 1988; Sinniah, 1980; Strata P, et 
al., 1995). In contrast, studies from United States have reported very low rates at 2 to 10 
percent, with the exception of a 38 percent incidence in the Navajo Indians in New Mexico 
(Julian et al., 1988). Nearly similar rates have been reported from Africa, Middle East, and 
some parts of Asia, including India, and Pakistan (Chandrika, 2009; D’Amico, 1985; 
Mubarak, 2009; Narasimhan et al., 2006; Seedat et al., 1988; Yahya et al., 1997). The exact 
cause for this marked variability in the epidemiology of the disease is not known, but it 
most probably is related to the differences in biopsy indications and the extent of 
pathologic evaluation of the renal biopsies.  
4. Etiology  
The vast majority of cases of IgAN are primary or idiopathic, and as their name suggests, 
their etiology is still not known (Barratt et al., 2004; Donadio & Grande, 2002; Floege & 
Feehally, 2000; Galla, 1995). The disease is, in most cases, a sporadic disorder. However, 
cases of familial and secondary IgAN are well documented and these have proved very 
useful for the insight they have provided for a better understanding of the pathogenetic 
mechanisms underlying the disease (Barratt et al., 2004; Donadio & Grande, 2002; Galla, 
1995). A list of these secondary causes is shown in table 1. 
 
 
Diseases of the liver: alcoholic, primary biliary, or cryptogenic cirrhosis; hepatitis B; 
chronic schistosomiasis 
Diseases of the gastrointestinal tract: celiac disease; chronic ulcerative colitis; Crohn’s 
disease 
Dermatologic diseases: dermatitis herpetiformis; psoriasis 
Pulmonary diseases: sarcoidosis, idiopathic pulmonary hemosiderosis; cystic fibrosis; 
bronchiolitis obliterans 
Malignant neoplasms: carcinoma of the lung, larynx, and pancreas; mycosis fungoides 
Infective agents: human immunodeficiency virus; leprosy 
Immunologic disorders: systemic lupus erythematosus; rheumatoid arthritis; 
cryoimmunoglobulinemia; psoriatic arthritis; ankylosing spondylitis; Sjögren’s 
syndrome; Behçet’s syndrome; Reiter’s syndrome; familial immune thrombocytopenia; 
Goodpasture’s syndrome 
Table 1. List of diseases/conditions associated with IgA deposits in the kidney.  
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5. The pathogenetic mechanisms 
The mechanism of development of IgAN is still largely unresolved. However, many  
advances have been made, especially during the last decade in unraveling some of the steps 
involved in the pathogenetic pathway of the disease. This has been made possible by the 
numerous experimental studies conducted on animal models and clinical studies in humans 
on the sporadic as well as rare genetic forms of the disease (Barratt et al., 2004; Donadio & 
Grande, 2002; Floege & Feehally, 2000; Galla, 1995).  The postulated mechanisms of 
pathogenesis are shown in Fig. 1.  
 
Mucosal immune dysfunction Defective galactosylation
Defective clearance of IgA1 by 
the liver
Increased formation of IgA1 in 
bone marrow
Binding of IgA1 to mesangial cells 
Deposition of IgA1 in the glomerular 
mesangium 
Production of growth factors and 
cytokines
Increased mesangial matrix formation and cell 
proliferation
 
Fig. 1. Schematic diagram showing the main steps involved in the pathogenesis of IgA 
nephropathy. The final common step consists of deposition of polymers of IgA1 molecules 
or their complexes in the mesangium. These, then induce injury and stimulate mesangial 
cells and recruited inflammatory cells to release mediators which result in the 
morphological expression of glomerular abnormaliteis.  
As is apparent from this figure, the final common pathway in the process consists of an 
accumulation of an abnormally galactosylated polymers of IgA1 (pIgA1) molecules and/or 
complexes in the mesangial regions of the glomeruli. It is plausible that numerous 
pathogenetic pathways are involved and converge on this central and unifying stage in the 
pathway (Barratt et al., 2004). The likely events of pathogenesis implicated in different 
studies run the whole span of IgA immune system abnormalities from increased production 
of aberrantly galactosylated pIgA1 molecules by a putative abnormal subclone of B 
lymphocytes, to decreased clearance by the liver, to host immune response to abnormal 
pIgA1 molecules, to physicochemical mechanisms leading to abnormal accumulation of 
pIgA1 in the mesangium (Coppo & Amore, 2004).  These bind to and interact with 
www.intechopen.com
 
Topics in Renal Biopsy and Pathology 
 
126 
mesangial cells leading to their activation and proliferation. Activated mesangial cells as 
well as infiltrating inflammatory cells, not only proliferate but also produce pro-
inflammatory cytokines, chemokines, and growth factors, which initiate tissue injury. A 
number of cytokines have been studied in detail including platelet derived growth factor 
(PDGF) β- chain and transforming growth factor-β (TGF- β) for their roles in the ultimate 
expression of the disease (Barratt et al., 2004; Donadio & Grande, 2002; Floege & Feehally, 
2000; Galla, 1995).  There is also evidence of local complement activation induced by 
alternative pathway triggered by pIgA1 molecules in the mesangium. There are species 
differences in the molecular structure of IgA and unique features of human IgA1 have 
prevented development of satisfactory animal models for the early stages of IgAN. A fully 
humanized mouse model of disease is still awaited to better extrapolate the steps of the 
pathogenesis to clinical disease in humans. It is probable that events downstream of pIgA1 
deposition, which result in glomerular inflammation and scarring, are not specific to IgAN 
but generic to many immune complex mediated forms of glomerulonephritis (Barrat et al., 
2004). There is also preliminary evidence in favor of genetic factors in the predisposition, 
development, and progression of the disease (Hsu et al., 2000). However, there is no single 
“IgA gene” involved, and it is likely that multiple interacting genes will eventually be 
discovered that predispose to the disease. More recently, IgAN has also been categorized as 
a form of auto-immune disease, in which autoantibodies of the IgG class are formed against 
aberrantly galactosylated IgA1 molecules. A complete understanding of the pathogenesis 
along with etiology is necessary if we are to develop a specific and targeted therapy for the 
disease. Future molecular biologic studies will certainly help in this discovery of missing 
steps in the pathogenesis (Barratt et al., 2004; Donadio & Grande, 2002; Floege & Feehally, 
2000; Galla, 1995; Novak et al., 2001). 
6. Pathology 
The diagnosis of IgAN on renal biopsy requires a detailed pathological evaluation of the 
biopsy by light microscopy (LM), IF, and electron microscopy (EM). In particular, IgAN is a 
diagnosis of IF microscopy. The features of IgAN on each of these investigations are 
described below: 
6.1 Light microscopy 
IgAN is primarily an immune-complex mediated GN, and like lupus nephritis manifests a 
wide range of morphological appearances on LM. Thus, on LM, IgAN is quite heterogenous. 
The range of morphologic alterations seen on renal biopsy under the LM spans the whole 
spectrum from minor changes in the glomeruli and the surrounding parenchyma to full 
blown crescentic GN (CresGN), except for pure membranous pattern. The list of 
morphological patterns seen in IgAN is shown in table 2 and in figures 2 to 6. All the above 
patterns of glomerular injury in IgAN are unified by the presence of predominant or co-
dominant IgA deposits in the glomerular mesangium on IF microscopy (Galla, 1995). The 
reason for this varying phenotypic expression of the disease in different patients is not 
completely known, but may be related to both the abnormalities of IgA molecule and the 
host factors. This phenotypic variability of IgAN on LM is expressed as clinical 
heterogeneity of the disease, but the clinical histologic correlation is not perfect. This 
variability in morphology of the disease has led to efforts to classify the disease into 
prognostic groups. 
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Light microscopy  
 
Glomeruli 
Minor changes 
Varying degrees of mesangial proliferation 
Mesangiocapillary pattern 
Focal segmental glomerular sclerosis  
Crescentic GN 
Diffuse proliferative and exudative GN 
Chronic sclerosing GN 
 
Tubulo-interstitial component 
Varying degrees of tubular atrophy and interstitial scarring, usually commensurate with 
glomerular changes 
 
Vascular changes 
Usually mild fibro-intimal thickening of arteries, commensurate with the degree and 
duration of hypertension 
Thrombotic microangiopathy 
 
Immunoflourescence  
IgA-dominant or co-dominant, is sine qua non for the diagnosis of IgA nephropathy 
Other immunoglobulins and complement components- variably present 
Lambda chain predominant  
 
Electron microscopy  
Variable degree of mesangial proliferation and glomerular inflammation 
Large electron dense deposits in the mesangium, paramesangium and occasionally, in 
other locations 
Table 2. Pathologic features of IgA nephropathy on light microscopy, immunoflourescence 
and electron microscopy.  
Many pathological classifications have been proposed over time, but none has achieved 
international acceptance (Hass, 1997; Manno et al., 2007). More recently, a new pathological 
classification of IgAN, termed “The Oxford classification of IgAN” has been formulated and 
published (Cattran et al., 2009; Roberts et al., 2009). It is unique and unprecedented type of 
classification that was validated before it was formulated and published, in contrast to the 
traditional approach to disease classifications. 
It is very simple and based on only four pathological features on renal biopsy and is easy to 
apply in routine practice. This classification is pre-validated, evidence based, and of good 
interobserver reproducibility and most important of all, proves independent prognostic 
value of pathological features on renal biopsy. Although, pre-validated, the scheme does 
require more validation studies in routine practice in prospective cohorts and in different 
study populations. The reasons are; although the sample size in the original study cohort 
was large, it was limited in scope, the retrospective design of the study, the use of only LM 
assessment for the classification, and most important of all, the unaddressed issue of 
treatment strategies. LM features are of independent prognostic value in IgAN and have 
been investigated by many researchers for classification purpose. 
www.intechopen.com
 
Topics in Renal Biopsy and Pathology 
 
128 
 
Fig. 2. Medium-power view showing a glomerulus with minor changes on light microscopy. 
Although rare, this pattern can be seen in IgA nephropathy. The surrounding tubules and 
interstitium show no significant pathology. (Jones’ methenamine silver, ×200).  
  
 
Fig. 3. Medium-power view showing two glomeruli showing mild prominence of the 
mesangium, but there is no significant increase in the mesangial cellularity in another case 
of IgA nephropathy. Surrounding parenchyma is unremarkable. (Jones’ methenamine silver, 
×200). 
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6.2 Immunoflourescence microscopy 
The sine qua non for the diagnosis of IgAN is the presence of dominant or co-dominant 
deposits of IgA in the mesangial area of the glomeruli on IF microscopy. The intensity of 
staining can vary from 1+ to 3+ on a semiquantitative scale of 0 to 3+ (Fig. 7). A trace 
positivity of IgA is not sufficient for the definitive diagnosis of IgAN. The distribution of 
IgA is predominantly mesangial, with extension of the deposits into peripheral capillary 
walls in approximately one third of cases. The deposited IgA consists mainly of IgA1 
rather than IgA2, and is accompanied by other immunoglobulins and complement 
components in many cases. IgG and IgM are frequently present, but their intensity is 
generally lower than that of IgA. In contrast, C3 deposits are almost universal and bright 
in intensity, whereas C1q is found only rarely and usually is of low intensity. The 
presence of dominant C1q with bright IgA should raise a differential diagnosis of lupus 
nephritis. Light chain typing of IgAN on IF shows a predominance of lambda light chains 
over kappa chains, a distinctive feature of IgAN. Fibrin may be found in severe forms  
of IgAN with crescent formation. Some IF features, such as peripheral capillary location  
of IgA and mesangial IgG, are supposedly of prognostic importance in IgAN (Bellur et  
al., 2011).  
 
 
 
 
 
 
Fig. 4. High-power view showing a glomerulus with segmental and moderate degree 
mesangial hypercellularity. The patchy involvement of the glomeruli is characteristic of IgA 
nephropathy. Peripheral capillary walls are thin and capillary lumena patent. The later 
features distinguishes this pattern from mesangiocapillary pattern. This is the typical and 
the most common morphological pattern seen in IgA nephropathy. (PAS, ×400). 
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Fig. 5. High-power view showing a segmental scar with adhesion formation with Bowman’s 
capsule. The unscarred portion of the glomerulus shows mild mesangial hypercellularity. 
This morphologic pattern is common in IgA nephropathy and is distinguished from 
idiopathic focal segmental glomerulosclerosis by the presence of IgA deposits on 
immunoflourescence and electron microscopy. (PAS, ×400). 
6.3 Electron microscopy 
Ultra-structurally, the main finding apart from the secondary changes of mesangial 
proliferation and other alterations, is the deposition of large, frequently triangular shaped, 
electron-dense deposits, most often, in the mesangium and para-mesangial area of the 
glomeruli (Fig. 8, 9). The deposits may on rare occasions be found in other locations within 
the glomeruli. The amount of deposits varies from case to case, and in some cases, massive 
deposits are found throughout the mesangium, extending into the sub-endothelial location. 
Peripheral capillary wall deposits in subepithelial, subendothelial, and intramembranous 
locations are found in approximately one fourth to one third of cases of IgAN. The deposits 
in these loci are more common in histologically severe forms of the disease, such as cresGN 
and rare in the mild forms of the disease. Electron-dense deposits may not occasionally be 
found in typical cases of IgAN diagnosed on IF microscopy. This does not rule out the 
diagnosis of IgAN, as the disease is a diagnosis of IF microscopy. Moreover, the deposits 
may be patchy and not included in the scanty material usually examined under the EM. 
In addition to the electron-dense deposits, the glomeruli show expansion of the mesangium 
and mesangial cell proliferation. These alterations parallel those seen on LM. There is also 
focal to diffuse loss of foot processes of podocytes, especially in those cases presenting with 
nephrotic range proteinuria. Focal areas of irregular thinning of GBM are seen in many cases  
of IgAN; these are not synonymous with concurrent IgAN and thin basement membrane 
disease (TBMD), and may contribute to the hematuria. Occasionally, IgAN co-exists with 
other glomerulopathies, such as TBMD, minimal change disease (MCD), membranous GN 
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(MN), etc. In those cases, features of both diseases will be found on ultrastructural study. No 
prognostic importance is attached with the ultrastructural alterations in IgAN. 
 
 
Fig. 6. High-power view showing a glomerulus with marked extracapillary cellular 
proliferation forming a crescent. The glomerular tufts are collapsed. This morphological 
pattern is rare in IgA nephropathy, but is well described, and leads rapidly to renal failure. 
(Jones’ methenamine silver, ×400). 
7. Clinical presentation 
Similar to its pathology and clinical course, IgAN is also heterogeneous in clinical 
presentation. It presents in a variety of ways. It can occur at any age, but majority of cases 
are seen in adolescents and young adults. The disease is more common in males than 
females, the male to female varying from less than 2:1 in Japan and other oriental studies to 
more than 6:1 in the studies from northern Europe and United States.  The classic 
presentation is with painless usually episodic gross or persistent microscopic hematuria, 
usually developing concurrently with upper respiratory tract infection (hence the use of 
synonym of synpharyngitic GN), gastroenteritis, or pneumonia. The presenting illness of 
episodic, grossly visible hematuria is more common in younger patients, whereas that of 
microscopic hematuria and proteinuria is more frequent in older individuals. Proteinuria is 
usually mild and usually associated with persistent microscopic hematuria. Occasional cases 
present with nephrotic range proteinuria. IgAN may rarely present with acute or chronic 
renal failure. Hypertension is rarely diagnosed at the time of presentation, but its frequency 
increases as the disease duration is increased or when patients develop ESRD (Barratt et al., 
2004; Donadio & Grande, 2002; Floege & Feehally, 2000; Galla, 1995).  
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8. Differential diagnosis 
A wide range of diseases are associated with the deposition of IgA in the glomeruli, and 
these come into the differential diagnosis of IgAN. The most common being Henoch-
Schonlein purpura (HSP), believed to be a systemic form of the same disease process as 
IgAN, with similar histopathological and IF findings in the glomeruli. The presence of 
systemic symptoms, such as purpuric rash, arthralgias, and abdominal pain help in this 
differential diagnosis. Post-infectious GN (PIGN) may also present with microscopic 
hematuria and comes in the clinical differential of IgAN, but the onset of hematuria 
occurs 7 to 14 days after, and not at the time of infection as in IgAN. A large number  
of other diseases are characterized by renal pathology resembling IgAN. These are  
listed in table 1 and are distinguished from primary IgAN by their associated signs and 
symptoms. 
 
 
Fig. 7. High-power view showing a glomerulus with diffuse, granular, strong (3+ on a scale 
of 0 to 3+) deposits of IgA in the mesangial regions. Focally, the deposits are extending into 
the peripheral capillary walls. (FITC-conjugated IgA, ×400). 
9. Risk of progression and classification systems 
Just like its morphology, the disease is also heterogeneous in its clinical evolution. Although 
the disease was traditionally considered as benign process, it is now known to lead to a 
slowly progressive decline in renal function with ESRD developing in upto 30-40% of 
patients 20 years after initial presentation (Barratt et al., 2004; Donadio & Grande, 2002; 
Galla, 1995; Geddes et al., 2003).  
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Fig. 8. Low-power electron photomicrograph showing mild mesangial proliferation 
associated with many large, triangular shaped, electron dense deposits in the mesangium. 
(Lead citrate & Uranyl acetate, ×5000). 
The clinical course in other patients is non-progressive, while in a minority of individuals it 
leads to a rapidly progressive course to ESRD. Most of the research is focused on identifying 
the predictive factors for the subset of patients with slowly progressive forms of the disease. 
Long term follow up studies show variable rates of disease progression in different parts of 
the world (Geddes et al., 2003). Many attempts have been made in recent past in identifying 
clinical, familial, laboratory, immunological, genetic, and morphologic features on renal 
biopsies which can predict the outcome in individual patients. However, many of these 
parameters have been investigated by simple univariate analysis, and the independent 
prognostic value of these factors has not been established. Among these, the predictive 
value of serial estimations of clinical and laboratory parameters is proved beyond any 
doubt. But whether, pathological features on renal biopsy are of any significant and 
independent predictive value has remained controversial till very recently. This is because 
of the fact that almost all pathologic studies carried out by different investigators in different 
parts of the world have produced conflicting results. Some investigators tried to incorporate 
the various morphological features observed under LM into a pathologic classification of 
IgAN, but none succeeded in achieving international approval (Hass, 1997; Lee et al., 2005; 
Manno et al., 2007). More recently, an international working group of nephrologists and 
nephropathologists with keen interest and expertise in IgAN have promulgated a novel 
classification of IgAN, termed “The Oxford classification of IgAN” (Cattran et al., 2009; 
Roberts et al., 2009).  
This scheme was developed by using a novel and unique approach to the pathological 
classification of IgAN, inasmuch as no arbitrary classes or grades are constructed, as in  
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Fig. 9. High-power electron photomicrograph showing large, triangular shaped, uniformly 
electron dense deposits in the para-mesangial regions of the glomerulus. (Lead citrate & 
Uranyl acetate, ×25000). 
previous classifications. Instead, specific pathological variables of prognostic importance 
independent of clinical data at the time of biopsy and follow up have been identified and 
scored by a rigorous iterative methodology of first defining the lesions and then testing for 
reproducibility and ease of scoring and finally testing them for their predictive power.  This 
type of rigorous effort has never been employed previously in the classification of renal 
diseases (Cattran et al., 2009; Roberts et al., 2009). The study cohort for the final study 
validation project consisted of 265 adults and children with biopsy-proven IgAN from eight 
different countries from four continents, with a median follow-up period of 5 years. The study 
cohort can be considered as fairly but not completely representative of the entire 
clinicopathological spectrum of IgAN. It included both males and females, children and 
adults, nearly all racial groups, and nearly all grades of severity of the disease. However, there 
was a marked underrepresentation of some grades of disease, for example, very mild cases 
and very severe cases were very few. This classification is based on detailed analysis of 
retrospective clinical data obtained on these patients in concert with intense and detailed 
pathological review of their renal biopsy material for the identified prognostic pathological 
features. Thus, the classification was validated before its formulation. A set of six distinct 
pathology variables were identified, from around 24 original pathological features tested, on 
the basis of sufficient reproducibility among the nephropathologists, least propensity for 
sampling error, and the ease of scoring in routine practice while avoiding strong co-linearity 
(mesangial hypercellularity score, segmental glomerulosclerosis or adhesion, endocapillary 
hypercellularity, cellular or fibrocellular crescents, tubular atrophy/interstitial fibrosis, artery 
score). Four of them (mesangial hypercellularity score, endocapillary hypercellularity, 
segmental glomerulosclerosis or adhesion, and tubular atrophy/interstitial fibrosis) were 
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shown in the final analysis to have independent predictive value for the final renal outcome 
even after taking into account all clinical and laboratory parameters available at the time of 
biopsy as well as during follow up. These pathological variables along with their proposed 
scoring (so called MEST score), which are recommended by the Oxford group, to be included 
in the pathology report of renal biopsy specimens from patients with IgAN, are shown in 
Table 3. These variables showed the independent prognostic value and a significant 
correlation with the clinical outcome in both univariate and multivariate analysis. The 
classification could not address the prognostic value of crescents due to their low prevalence in 
the enrolled cohort which did not include rapidly progressive cases. This classification is 
clinically pre-validated, evidence based with acceptable interobserver reproducibility, and 
most important of all, relatively simple to apply in routine practice (Cattran et al., 2009; 
Mubarak, 2009; Roberts et al., 2009). The case mix was fairly varied; the cases were collected 
from eight different centers from four main continents, to ensure international participation 
and consensus development. However, there are certain limitations of the classification 
scheme; the classification was developed by dedicated, research-oriented nephropathologists 
with special interest in IgAN and on a limited repertoire of cases. As discussed previously, 
both mild (non-progressive) and severe (rapidly-progressive) ends of IgA spectrum were not 
enrolled. It was retrospective by design and the impact of treatment was not explored in detail. 
There is definitely a scope for further refinement and validation of the scheme in other 
prospective cohorts of patients. It needs to be validated in routine practice among practicing 
pathologists throughout the world on a wide range of cases (Herzenberg et al., 2011). 
Moreover, the original classification is based purely on light microscopic assessment of 
pathological features on renal biopsies (Mubarak, 2009). No correlation with IF or EM 
variables was carried out during the development of this classification. More recently, the 
question of clinical value of immunohistologic findings in the context of the original study 
patients’ cohort has been addressed by the core group of the researchers involved in the 
development of the original classification (Bellur et al., 2011). They conclude that the 
glomerular location of IgA and the presence of IgG correlate with mesangial and endocapillary 
cellularity. It is likely that the immunohistologic findings may be added to the classification in 
near future as more data accumulate.  
 
Pathological features       Score 
 
1. Mesangial hypercellularity 
Present in ≤50% of the glomeruli      M0 
Present in >50% of the glomeruli      M1 
2. Endocapillary hypercellularity 
Absent         E0 
Present         E1  
3. Segmental glomerulosclerosis 
Absent         S0 
Present         S1 
4. Tubular atrophy/interstitial fibrosis 
≤ 25% of the cortex      T0 
26–50% of the cortex      T1 
>50% of the cortex      T2 
Table 3. The four key pathological features that are recommended by the Oxford group to be 
included in the standardized pathology reports for patients with IgA nephropathy.  
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There is also need to investigate the effect of additional features which had enrollment bias 
in the original study ( rapidly progressive and non-progressive cases) and to investigate the 
combined prognostic value of adding clinical data to biological scores (e.g. proteinuria at the 
time of renal biopsy or during follow-up), and the last, but not the least, to detect for each 
lesion, the most effective treatment and the point of no return when no treatment is 
effective.  
10. Future prospects 
During recent past, a series of important advancements in the areas of molecular 
pathogenesis and experimental therapy have taken place, reflected in a molecular paradigm 
shift in the techniques and approaches applied to the study of IgAN (Novak et al., 2001). 
Ongoing and future investigations in this area will lead to the development of new non-
invasive molecular tests for the diagnosis and prognosis, and the application of these 
discoveries to the rational design of tailored therapeutic agents.  
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